The US Food and Drug Administration has approved the first bispecific antibody medicine for the eye – a treatment that targets two pathways thought to contribute to vision loss by destabilising blood vessels. The drug, Vabysmo (faricimab-svoa), has been authorised for the treatment of neovascular or ‘wet’ age-related macular degeneration (AMD) and diabetic macular oedema. Both diseases impair central vision, with the latter affecting people with Type 1 and Type 2 diabetes.
